Estrella Immunopharma (ESLA) Share-based Compensation (2021 - 2026)
Estrella Immunopharma (ESLA) posted quarterly Share-based Compensation of $146714.0 for Q1 2026, down 7.78% year-over-year from $159095.0 in Q1 2025, and down 1.11% quarter-over-quarter from $148360.0 in Q4 2025.
Estrella Immunopharma (ESLA) Share-based Compensation (2021 - 2026) Analysis & Trends
Estrella Immunopharma (ESLA) has reported Share-based Compensation for 6 consecutive years, with $146714.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Share-based Compensation fell 7.78% year-over-year to $146714.0; the TTM figure through Mar 2026 stood at $606593.0 (up 2.58% YoY), while the FY2025 annual figure was $618974.0, up 43.2% from the prior year.
- Share-based Compensation eased to $146714.0 in Q1 2026 per ESLA's latest filing, from $148360.0 in the prior quarter.
- Across five years, Share-based Compensation topped out at $1.2 million in Q3 2023 and bottomed at $102399.0 in Q3 2022.
- Historically, Share-based Compensation has averaged $300699.1 across 5 years, with a median of $159096.5 in 2025.
- Annual changes were most pronounced in 2023 — Share-based Compensation surged 1066.66% — and 2025, when it slumped 65.68%.
- Estrella Immunopharma's Share-based Compensation stood at $204798.0 in 2022, then soared by 483.33% to $1.2 million in 2023, then slumped by 63.82% to $432256.0 in 2024, then plunged by 65.68% to $148360.0 in 2025, then declined by 1.11% to $146714.0 in 2026.
- Business Quant data shows ESLA's Share-based Compensation at $146714.0 in Q1 2026, $148360.0 in Q4 2025, and $152421.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 86.63 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 41.25 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 28.05 Mn |
| 10 | Estrella Immunopharma | 32.24 Mn | 32.10 Mn | - | 145,298.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 145,298.00 |
| Jun 30, 2026 | 145,298.00 |
| Mar 31, 2026 | 146,714.00 |
| Mar 31, 2026 | 146,714.00 |
| Dec 31, 2025 | 148,360.00 |
| Dec 31, 2025 | 148,360.00 |
| Sep 30, 2025 | 152,421.00 |
| Sep 30, 2025 | 152,421.00 |
| Jun 30, 2025 | 159,098.00 |
| Jun 30, 2025 | 159,098.00 |
| Mar 31, 2025 | 159,095.00 |
| Mar 31, 2025 | 159,095.00 |
| Dec 31, 2024 | 432,256.00 |
| Dec 31, 2024 | 432,256.00 |
| Sep 30, 2023 | 1.19 Mn |
| Sep 30, 2023 | 1.19 Mn |
| Mar 31, 2023 | 307,197.00 |
| Mar 31, 2023 | 307,197.00 |
| Dec 31, 2022 | 204,798.00 |
| Dec 31, 2022 | 204,798.00 |